From Yahoo Finance: 2025-04-19 10:00:00

Warren Buffett suggests holding stocks forever, as predicting stock performance is difficult. Iovance Biotherapeutics is a small but high-growth company with revenue expected to soar by 180% this year and 45% next year. The company’s first drug approval for a T-cell therapy for melanoma has propelled its growth. The immunotherapy market is set to grow significantly, with Iovance expected to be a key player. Despite recent stock decline, analysts rate Iovance as a strong buy with a price target over 500% higher than its current price, making it a potential long-term investment opportunity.



Read more at Yahoo Finance: This Biotech Stock Could Be the Best Investment of the Decade